News Archive

Facebook has been making tentative steps in the health tech realm. I’m not referring to Mark Zuckerberg’s philanthropic ambitions. But the social media network has demonstrated an interest in some diverse areas from genomic testing to public health. There’s even more going on with its Internet.org division but the company has been pretty tight-lipped about new developments on this front with most information on healthcare projects coming from entrepreneurs rather than the technology company. Here are a few areas that could grow in 2016.

Medical technology is slated to be a $40 billion market in India by 2025. But it’s largely ignored, says Siraj Dhanani, founder of InnAccel, India’s first medical technology incubator.

“It’s a market that’s suboptimally served, and there are global models for med-tech innovation that can be successfully implemented in India,” he says, seated in his Bangalore office.

The 2015 return of 12.3% for the NASDAQ Biotechnology Index ETF makes the biotech sector one of the market’s best-performing baskets this year, and the returns of the five best biotech stocks in the space were downright mind-boggling. All five of these biotech companies boast billion-dollar market caps, and each has seen its shares post eye-popping returns of nearly 200% or more this year. Let’s find out why.

Here are three things we can agree on. Some predictions are good. Some predictions are bad. Most predictions are wrong.

Stephanie Baum, Meghana Keshavan and I spent the last fews days spouting off on the kind of deals we think should happen in healthcare in 2016. Afterward, we polled the full MedCity News reporting staff and incorporated feedback from social media to rank these healthcare M&A predictions from completely loony tunes and to actually having some merit.

As the year draws to a close, I want to reflect on FDA’s many accomplishments in these previous 12 months, the last nine of which it has been my pleasure to serve as Acting Commissioner. FDA has broad responsibilities – indeed, we are tasked with overseeing products that account for about 20 cents of the consumer dollar — so we work on a wide range of topics in any given year. In this and two additional blog posts over the coming days I’ll cover some of our key accomplishments in 2015. Each blog will examine a different area of FDA’s work. This first post will focus on medical product innovation – our role in making safe, effective and innovative products available to patients who need them.

Older adults can be the focus of emerging digital health firms.   Kudos to Aging 2.0 and its effort to find an attract startups that can help older adults.  So much of the Digital Health landscape acts, just like Apple, agnostic about age, avoiding the chance to shape a market message for products that clearly could benefit (and in Apple’s case, do benefit) older adults. Even more striking is the percentage of health care costs that are actually spent on older adults.  For other age-indifferent health-related see Connected Health Symposium and mHealth Summit for too many examples. But Aging 2.0 has a different agenda than these — welcoming the messaging about age and inviting companies that these other events might (or might not) welcome in LivePitch events. Here are a few of the companies in the Digital Health space pitching for pilots at Aging 2.0. Material is from the companies’ websites: 

Most people would agree that it would be better to prevent cancer, if we could, than to treat it once it developed. Yet economic incentives encourage researchers to focus on treatment rather than prevention.

The way the patent system interacts with the Food and Drug Administration’s drug approval process skews what kinds of cancer clinical trials are run. There’s more money to be made investing in drugs that will extend cancer patients’ lives by a few months than in drugs that would prevent cancer in the first place.

Bethesda-based Northwest Biotherapeutics Inc. is raising $12.6 million in new funding as part of a direct offering to health care-focused investors, according to a company announcement.

We are at the beginning of a transformation in human health, treating diseases in ways that we could only speculate about in the recent past. While biology isn’t quite engineering (yet), biotech has become a technology-based, high-growth, high-wage space, all while working to cure cancer. Doing well by doing good. It is more than a business.

As we look back on the medtech developments of 2015 there’s definitely a sense that we’re living through revolutionary times. Nearly every day exciting and fascinating technologies are being unveiled by small and large companies, universities, and even tiny independent groups. Empowered by high-powered computers, 3D printers, and other technologies, researchers, scientists, and engineers are coming up with novel solutions to age-old medical problems. Everything from treating gunshot wounds to how fetuses inside the womb are monitored is going through change thanks to technologies developed by thousands of independent minds around the world.